An Evaluation of a Non-invasive Brain Monitor

Brain Injuries Clinical Trial

Official title:

An Open-Label, Non-Randomized, Comparative Study Designed to Evaluate the Accuracy and Safety of HS-1000 Device, a Non-Invasive Brain Monitor

Clinical Trial Details — Status: Unknown status

Administrative data

• NCT number: NCT02775136
• Other study ID #: HS-011
• Status: Unknown status
• Phase: N/A
• Start date: October 2014
• Est. completion date: December 2017

Study information

• Verified date: December 2016
• Source: HeadSense Medical
• Contact: Thomas Swanson
• Email: thomas[@]head-sense-med.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

HS-1000 device, a proprietary new non-invasive brain monitor, is expected to safely and accurately monitor physiological signs of the brain with minimal discomfort to patients, providing information about normal or abnormal brain-related conditions and providing decision-making support for physicians. Investigators hypothesis that the HS-1000 is capable of detecting and monitoring various neuropathologies, using the acoustic raw data derived from the noninvasive procedure.

Description:

Non-invasive modality for brain monitoring can potentially serve as a major contribution to conventional monitoring techniques for patients with neuropathologies, to assure minimal discomfort to the bedbound patients, and provide information about critical physiological signs to the physicians. The lack of a precise diagnostic technique for numerous neuropathologies for patients in neurosurgical clinics can further hinder therapeutic effectiveness and, therefore, influence patient recovery and healing. Neuro-critical care involves monitoring standard vital signs and cerebral physiological signs, mainly focusing on intracranial pressure (ICP), temperature, cerebral blood flow velocity, arterial blood pressure, cerebral perfusion pressure, brain tissue oxygenation etc. The collaboration of state of the art brain monitoring vary between different intensive care units serves a significant drawback in some cases, as accuracy of diagnosis and monitoring is challenged and thereby there is an eminent need for interrelationship brain monitoring approach. That can also be leveraged by applying the monitoring noninvasively, as it particularly beneficial for clinical applications that routinely require the inevitable and dynamic transport of patients between hospital units (imaging, surgical room, etc.).

Subjects who meet the inclusion and exclusion criteria for this study, with a signed informed consent form, will be enrolled into the study. Eligible patients will be divided to 2 groups:

1. Patients undergoing Invasive ICP monitoring

2. Subarachnoid hemorrhage (SAH) patients with Fisher Grade of 3 or 4

The non-invasive measurements recording sessions will be according to the protocol scheme per each group:

1. Eligible patients undergoing Invasive ICP monitoring will be monitored by the HS-1000, in parallel to the invasive ICP monitor, for a single recording session.

2. Eligible SAH patients with Fisher Grade of 3 or 4 will be monitored by the HS-1000, in parallel to the invasive ICP monitor, for three recording sessions.

For all eligible patients, non-invasive measurements by the HS-1000 device will be conducted in parallel with the standard monitoring modalities, as used at the site without any change in the patient's management.

Recruitment information / eligibility

• Status: Unknown status
• Enrollment: 160
• Est. completion date: December 2017
• Est. primary completion date: June 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Adult men and women subjects, aged 18 years old and over at screening visit

2. Subjects with neuropathology that the principal investigator considers including in this study.

3. Survival expectancy greater than 72 hours

4. Subject or legal authorized representative (per local regulation) is able and willing to comply with the requirements of the protocol

5. Subject or legal authorized representative (per local regulation) is able to understand and sign written informed consent to participate in the study

Exclusion Criteria:

1. Local ear infection

2. Known allergy or hypersensitivity to any of the test materials or contraindication to test materials

3. For women of childbearing potential: pregnancy (positive pregnancy test) or breast-feeding

4. Subarachnoid hemorrhage (SAH), Fisher Grade 4

5. Subjects currently enrolled in or less than 30 days post-participation in other investigational device or drug study(s), or receiving other investigational agent(s)

6. Any condition that may jeopardize study participation (e.g., abnormal clinical or laboratory finding) or interpretation of study results, or may impede the ability to obtain informed consent (e.g., mental condition)

Related Conditions & MeSH terms

• Brain Injuries
• Brain Neoplasms
• Hemorrhage
• Hydrocephalus
• Subarachnoid Hemorrhage
• Vasospasm, Intracranial

Intervention

Device:
• HS-1000 recording

Locations

Country	Name	City	State
Germany	Klinikum Darmstadt	Darmstadt
Germany	University Hospital Erlangen	Erlangen
Germany	Universitätsklinik Göttingen	Gottingen
Germany	Klinikum Stuttgart	Stuttgart

Sponsors (4)

Lead Sponsor	Collaborator
HeadSense Medical	Klinikum Darmstadt, Klinikum Stuttgart, University Medical Center Goettingen

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of recordings that correlate to neuropathology	Demonstrate the HS-1000 performance and accuracy in brain monitoring	up to 1 hour
Secondary	Incidence of adverse events		48 hours from the end of monitoring with the HS-1000
Secondary	Rate of ear infections/irritations graded by none/mild/moderate and severe		48 hours from the end of monitoring with the HS-1000